Literature DB >> 19015334

Impact of inoculum size and heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) on vancomycin activity and emergence of VISA in an in vitro pharmacodynamic model.

Warren E Rose1, Steven N Leonard, Kerri L Rossi, Glenn W Kaatz, Michael J Rybak.   

Abstract

The activity of vancomycin against heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) and non-hVISA isolates, using an in vitro pharmacodynamic model, was reduced in the presence of a high inoculum amount (10(8) CFU/ml). A high bacterial load of >10(5) CFU/ml persisted for all strains with doses up to 5 g every 12 h against high inoculum amounts. No change in the vancomycin MIC was detected in any isolate at a moderate inoculum amount (10(6) CFU/ml), and bactericidal activity occurred only against the non-hVISA isolate (time to 99% kill, 7.5 h; P = 0.001).

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19015334      PMCID: PMC2630635          DOI: 10.1128/AAC.01009-08

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  8 in total

1.  Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility.

Authors:  Benjamin P Howden; Peter B Ward; Patrick G P Charles; Tony M Korman; Andrew Fuller; Philipp du Cros; Elizabeth A Grabsch; Sally A Roberts; Jenny Robson; Kerry Read; Narin Bak; James Hurley; Paul D R Johnson; Arthur J Morris; Barrie C Mayall; M Lindsay Grayson
Journal:  Clin Infect Dis       Date:  2004-01-29       Impact factor: 9.079

2.  Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin.

Authors:  K Hiramatsu; N Aritaka; H Hanaki; S Kawasaki; Y Hosoda; S Hori; Y Fukuchi; I Kobayashi
Journal:  Lancet       Date:  1997-12-06       Impact factor: 79.321

3.  Inoculum effects of ceftobiprole, daptomycin, linezolid, and vancomycin with Staphylococcus aureus and Streptococcus pneumoniae at inocula of 10(5) and 10(7) CFU injected into opposite thighs of neutropenic mice.

Authors:  Dong-Gun Lee; Yoichi Murakami; David R Andes; William A Craig
Journal:  Antimicrob Agents Chemother       Date:  2013-01-07       Impact factor: 5.191

4.  Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections.

Authors:  Pamela A Moise-Broder; Alan Forrest; Mary C Birmingham; Jerome J Schentag
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

5.  Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model.

Authors:  Kerry L LaPlante; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

6.  A multicenter study evaluating the current strategies for isolating Staphylococcus aureus strains with reduced susceptibility to glycopeptides.

Authors:  Mandy Wootton; Alasdair P MacGowan; Timothy R Walsh; Robin A Howe
Journal:  J Clin Microbiol       Date:  2006-11-15       Impact factor: 5.948

7.  Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus.

Authors:  Patrick G P Charles; Peter B Ward; Paul D R Johnson; Benjamin P Howden; M Lindsay Grayson
Journal:  Clin Infect Dis       Date:  2004-01-12       Impact factor: 9.079

8.  Prevalence and characteristics of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia in a tertiary care center.

Authors:  Yasmin Maor; Galia Rahav; Natasha Belausov; Debby Ben-David; Gill Smollan; Nathan Keller
Journal:  J Clin Microbiol       Date:  2007-03-07       Impact factor: 5.948

  8 in total
  14 in total

1.  Preferential emergence of reduced vancomycin susceptibility in health care-associated methicillin-resistant Staphylococcus aureus isolates during continuous-infusion vancomycin therapy in an in vitro dynamic model.

Authors:  Sheryl Zelenitsky; Noha Alkurdi; Zhanni Weber; Robert Ariano; George Zhanel
Journal:  Antimicrob Agents Chemother       Date:  2011-04-18       Impact factor: 5.191

2.  Optimization of Synergistic Combination Regimens against Carbapenem- and Aminoglycoside-Resistant Clinical Pseudomonas aeruginosa Isolates via Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling.

Authors:  Rajbharan Yadav; Jürgen B Bulitta; Roger L Nation; Cornelia B Landersdorfer
Journal:  Antimicrob Agents Chemother       Date:  2016-12-27       Impact factor: 5.191

3.  Sequential Evolution of Vancomycin-Intermediate Resistance Alters Virulence in Staphylococcus aureus: Pharmacokinetic/Pharmacodynamic Targets for Vancomycin Exposure.

Authors:  Justin R Lenhard; Tanya Brown; Michael J Rybak; Calvin J Meaney; Nicholas B Norgard; Zackery P Bulman; Daniel A Brazeau; Steven R Gill; Brian T Tsuji
Journal:  Antimicrob Agents Chemother       Date:  2015-12-28       Impact factor: 5.191

4.  Clinical Outcomes in Patients with Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Bloodstream Infection.

Authors:  Anthony M Casapao; Steven N Leonard; Susan L Davis; Thomas P Lodise; Nimish Patel; Debra A Goff; Kerry L LaPlante; Brian A Potoski; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2013-06-24       Impact factor: 5.191

5.  Vancomycin and maltodextrin affect structure and activity of Staphylococcus aureus biofilms.

Authors:  Mia Mae Kiamco; Erhan Atci; Qaiser Farid Khan; Abdelrhman Mohamed; Ryan S Renslow; Nehal Abu-Lail; Boel A Fransson; Douglas R Call; Haluk Beyenal
Journal:  Biotechnol Bioeng       Date:  2015-09-02       Impact factor: 4.530

Review 6.  Use of vancomycin pharmacokinetic-pharmacodynamic properties in the treatment of MRSA infections.

Authors:  Christopher Giuliano; Christopher Giulano; Krystal K Haase; Ronald Hall
Journal:  Expert Rev Anti Infect Ther       Date:  2010-01       Impact factor: 5.091

7.  Vancomycin AUC/MIC ratio and 30-day mortality in patients with Staphylococcus aureus bacteremia.

Authors:  Natasha E Holmes; John D Turnidge; Wendy J Munckhof; J Owen Robinson; Tony M Korman; Matthew V N O'Sullivan; Tara L Anderson; Sally A Roberts; Sanchia J C Warren; Wei Gao; Benjamin P Howden; Paul D R Johnson
Journal:  Antimicrob Agents Chemother       Date:  2013-01-18       Impact factor: 5.191

8.  Heterogeneous vancomycin-intermediate susceptibility phenotype in bloodstream methicillin-resistant Staphylococcus aureus isolates from an international cohort of patients with infective endocarditis: prevalence, genotype, and clinical significance.

Authors:  In-Gyu Bae; Jerome J Federspiel; José M Miró; Christopher W Woods; Lawrence Park; Michael J Rybak; Thomas H Rude; Suzanne Bradley; Suzana Bukovski; Cristina Garcia de la Maria; Souha S Kanj; Tony M Korman; Francesc Marco; David R Murdoch; Patrick Plesiat; Marta Rodriguez-Creixems; Porl Reinbott; Lisa Steed; Pierre Tattevin; Marie-Françoise Tripodi; Karly L Newton; G Ralph Corey; Vance G Fowler
Journal:  J Infect Dis       Date:  2009-11-01       Impact factor: 5.226

Review 9.  Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications.

Authors:  Benjamin P Howden; John K Davies; Paul D R Johnson; Timothy P Stinear; M Lindsay Grayson
Journal:  Clin Microbiol Rev       Date:  2010-01       Impact factor: 26.132

10.  Synergy between vancomycin and nafcillin against Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model.

Authors:  Steven N Leonard
Journal:  PLoS One       Date:  2012-07-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.